Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Three distributors and a drugmaker may avert the first federal trial over their role in the U.S. opioid crisis.
The risks are lower than ever—and could save patients months on organ waitlists.
The drug can quickly reverse opioid-driven overdoses.
A recent opinion piece in the Columbia Journalism Review argues that the distinction matters.
Judge’s ruling may pave the way for opening the nation’s first supervised overdose prevention facility.
Efforts to control viral hepatitis are falling behind, in part because of the growing opioid epidemic and homelessness crisis.
A literature review shows promising signs that teenagers, like adults, can benefit from methadone, buprenorphine and naltrexone.
Justice Department lawyers are fighting against a Philadelphia nonprofit’s latest proposal to open one.
A new report warns the crisis could see a third wave if synthetic opioids continue to move into new U.S. markets.
Two new interactive (and free!) databases offer maps, policies and much more, courtesy of amfAR.
The drug can quickly reverse an opioid overdose and prevent death.
The first national study of opioid use disorder recovery found that staying off such drugs often requires great effort and various services.
Massive legal payouts are likely coming—but it’s still unclear where they will go.
The danger of prescription painkillers might have been overestimated and too little was done to identify those most at risk for addiction.
But the health secretary does not support safe injection sites.
The head of the Food and Drug Administration cited a long commute and time away from family as reasons to step down.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.